Breaking Down Regeneron Pharmaceuticals: 13 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
Analysts have varied opinions on Regeneron Pharmaceuticals (NASDAQ:REGN), with recent ratings ranging from bullish to bearish. The average 12-month price target is $1072.38, indicating a 6.11% increase from the previous target. Analyst actions include rating changes and price target adjustments, reflecting market dynamics and company performance. Regeneron develops and commercializes treatments for diseases, showing substantial market capitalization but facing challenges in revenue growth, net margin, ROE, and ROA compared to industry averages.
April 12, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron Pharmaceuticals has received diverse analyst ratings, with a new average 12-month price target suggesting a 6.11% increase. Despite its strong market position, the company faces challenges in revenue growth, profitability, and asset utilization.
The diverse analyst ratings and the upward revision of the 12-month price target suggest optimism about Regeneron's future stock performance. However, the company's challenges in revenue growth, net margin, ROE, and ROA, compared to industry averages, may temper this optimism. The importance of these analyst ratings and financial metrics is high as they provide insights into the company's market standing and financial health, influencing investor sentiment and potentially the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100